Investment

Switched to open-ended strategy

PGIM Investments survey

Huw Price also joins

Portfolio Managers Andy Acker and Agustin Mohedas explain why shares of companies delivering next-generation therapies for inflammation and immunology (I&I) disorders could have plenty of room to run.

First dedicated UK strategy

Non-executive director

Passive funds continue to dominate

‘You cannot have it both ways’

'Not all bankers will welcome the change'

Investment Week has partnered with Carmignac, Invesco, LGIM, Quilter, Schroders and Tatton to bring an exclusive guide that explores the trends driving the increasing use of the model portfolio services.